claim
Olson and collaborators are developing psychotropic drugs that maintain mental health benefits while minimizing subjective hallucinogenic effects, as cited in Duman and Li (2012), Hesselgrave et al. (2021), and Ly et al. (2018).

Authors

Sources

Referenced by nodes (1)